UNSPSC 51391739: Salmeterol

This classification denotes a bronchodilator with the molecular formula C25H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2I4BC502BT, chemically known as 1,3-benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)- but generally known as salmeterol, which bears US NIH Compound Identifier 5152. European Medicines Agency schedules Salmeterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10430MIG.

UNSPSC 51391739 Salmeterol is a Commodity code that covers pharmaceutical products, but the recent state and local opportunities posted under this code show limited alignment with the nominal scope. The Seminole County, Florida procurement (IFB 60459723LAS) sought naloxone and drug deactivation systems rather than salmeterol; the Texas Health and Human Services Commission RFI (HHS0017013) addressed direct-to-manufacturer prescription programs and pharmacy benefit management strategy, not a specific pharmaceutical product. State and local governments do procure medications and pharmaceutical supplies through their health departments, county health systems, and Medicaid agencies, but the recent activity under this code does not reflect that procurement pattern. The issuing bodies in the available records — Seminole County and the Texas HHS Commission — represent typical state and county health and social services buyers, but the mismatch between the code's product name and the work actually being solicited suggests this code sees minimal relevant recent activity in state and local procurement channels.

Geographic activity is concentrated in the South, with Florida and Texas appearing in the recent record. No other states or jurisdictions show recent opportunities tagged to this code. The Seminole County IFB required quarterly naloxone and deactivation-system deliveries to the Seminole County Community Health Building in Sanford, Florida, with an initial two-year contract term and one-year renewal option, opening for bids on July 10, 2023, with a final response deadline of July 26, 2023. The Texas RFI, posted April 3, 2026, was exploratory in nature and did not commit to a formal solicitation timeline or award. Practitioners evaluating salmeterol or other specific pharmaceutical commodities should cross-reference broader pharmaceutical-supply and pharmacy-benefit codes, as state and local health procurement often does not align cleanly with single-product UNSPSC classifications.